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CTRP3Rheumatoid arthritis (RA) is an autoimmune inﬂammatory disease exhibited most commonly in joints.
We found that the expression of C1qtnf3, which encodes C1q/TNF-related protein 3 (CTRP3), was highly
increased in two mouse RA models with different etiology. To elucidate the pathogenic roles of CTRP3
in the development of arthritis, we generated C1qtnf3/ mice and examined the development of colla-
gen-induced arthritis in these mice. We found that the incidence and severity score was higher in
C1qtnf3/ mice compared with wild-type (WT) mice. Histopathology of the joints was also more severe
in C1qtnf3/mice. The levels of antibodies against type II collagen and pro-inﬂammatory cytokinemRNAs
in C1qtnf3/ mice were higher than WTmice. These observations indicate that CTRP3 plays an important
role in the development of autoimmune arthritis, suggesting CTRP3 as a possible medicine to treat RA.
 2013 The Authors. Published by Elsevier Inc. Open access under CC BY license.1. Introduction
Rheumatoid arthritis (RA) is an autoimmune disease that causes
inﬂammation and bone destruction most commonly in joints.
Inﬂammatory cytokines such as IL-1, IL-6, TNF-a, and IL-17 play
important roles for the development of RA, and antibodies and
inhibitors against these cytokines are successfully used for the
treatment of RA [1,2]. As high titers of autoantibodies are detected
in the serum of RA patients, antibodies against B cells are also use-
ful for the treatment of RA [3]. These approaches have signiﬁcantly
improved the efﬁcacy of RA treatment. However, because some
patients are refractory to these treatments or become refractoryduring these treatments, the development of new therapeutics is
still awaited.
We previously generated two RA models; one is human T-cell
leukemia virus type I (HTLV-I) transgenic (Tg) mice and the other
is IL-1 receptor antagonist (IL-1Ra) deﬁcient (KO) mice, both of
which spontaneously develop autoimmune arthritis [4,5]. Because
multiple genes are implicated in the development of autoimmune
diseases, we searched for novel disease-related genes using DNA
microarray techniques. As a result of comprehensive gene expres-
sion analysis between RA models and wild-type (WT) mice, we
identiﬁed 554 genes of which expression changed more than 3
times in both RA models compared with WT mice [6]. The C1qtnf3
gene, which encodes CTRP3 (also named CORS-26, cartducin and
cartnectin), is one of such genes and is highly expressed in both
models.
CTRP3 is a soluble secreted protein consisted of a short N-termi-
nal variable region, collagen domain and C-terminal C1q domain.
CTRP3 belongs to a member of C1q/TNF-related protein (CTRP)
family, having a crystal structure resembling TNF and complement
C1q [7]. The C1q domain may be important for the binding to the
receptor, although the receptor has not been identiﬁed yet, be-
cause the C1q domain of complement C1q and adiponectin, one
of CTRP family members, is important for the recognition and bind-
ing to their receptors. CTRP family members are involved in host
defense, inﬂammation and glucose metabolism [7], and CTRP3 is
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drogenic precursors and chondrocytes [8]. Recently, it was re-
ported that CTRP3 inhibits LPS-induced inﬂammatory cytokine
production from human adipocytes, monocytes and ﬁbroblasts
[9–11]. However, the physiological roles of CTRP3 in vivo still
remain to be elucidated. In this study, we have generated
C1qtnf3/ mice, and investigated the effect of CTRP3 deﬁciency
on the development of autoimmune arthritis.2. Materials and methods
2.1. Generation of C1qtnf3/ mice
Table 1 Genomic DNA containing C1qtnf3 gene was isolated
from EGR-101 ES cells derived from C57BL/6 embryos [12]. The tar-
geting vector was constructed by replacing a 170 bp genomic frag-
ment containing the exon 4 of the C1qtnf3 gene, which encodes the
C1q domain, with the 1.7 Kb DNA fragment containing neomycin
resistance gene (Neor) under the PGK1 promoter which was ﬂanked
by the loxP sequences. For the negative selection, a diphtheria toxin
(DT) A gene under the MC1 promoter was ligated to the 30 end of
the targeting vector. The targeting vector was electroporated into
ES cells and G418-resistant clones were selected (Nacalai Tesque,
Japan). Homologous recombinant ES clones were screened by
PCR and Southern blotting using primers and probes as indicated
in Fig. 1. Chimeric mice were generated by an aggregation method
[13]. The genotyping of C1qtnf3-deﬁcient mice was carried out
using the following PCR primers: primer 1, 50-GATGCAGAGCAA-
TATCACACAG-30; primer 2, 50-GTTGATTCTTGCATCTCACCTG-30; pri-
mer 3, 50-GCTCGGTACCCATCAAGCTTAT-30. Primer 1 and 2 were
used to detect WT-allele (336 bp), and primer 1 and 3 were used
to detect mutant-allele (195 bp). The lack of C1qtnf3 transcripts
was conﬁrmed by RT-PCR using the following PCR primers: 50-
CTTCAGCATGTACAGCTATG-30 and 50-GTTGCCCATTCTTAGCCAG-
ACT-30.
We used 8–10 week-old C57BL/6 background mice of the same
sex in all experiments. Mice were kept under SPF conditions in the
clean rooms at the Center for Experimental Medicine and Systems
Biology, Institute of Medical Science, University of Tokyo and the
Research Institute for Biomedical Sciences, Tokyo University of Sci-
ence. All experiments were approved by the institutional animal
use committees and were conducted according to the institutional
ethical guidelines for animal experiments and safety guidelines for
gene manipulation experiments.
2.2. In vitro complement activation assay
Plates (Nunc, Denmark) were coated with OVA/anti-OVA
immune complex (OVA: Sigma, USA, and anti-OVA Ab: Millipore,
Germany), 50 lg/ml mannans (Sigma, USA), or 200 lg/ml LPS
(Sigma, USA) for the assay of complement activation of the classical
pathway (CP), lectin pathway (LP) and alternative pathway (AP),
respectively [14,15]. Serum was diluted with GVB++ buffer for the
assay of the CP and LP activity and with GVB/Mg2+ EGTA buffer
for the AP activity. 10% serum was incubated on plates at 37 CTable 1
Primers for quantitative real-time PCR.
Gene
name
Forward primer Reverse primer
C1qtnf3 CTTCAGCATGTACAGCTATG GTTGCCCATTCTTAGCCAGACT
Gapdh TTCACCACCATGGAGAAGGC GGCATGGACTGTGGTCATGA
Tnf GCCTCCCTCTCATCAGTTCT CACTTGGTGGTTTGCTACGA
Il1b CAACCAACAAGTGATATTCTCCATG GATCCACACTCTCCAGCTGCA
Il6 ACAATTGCCAATCTGTCGAA CAAGCCTCGCGACCATTCTTGA
Il10 GCTCTTACTGACTGGCATGAG CGCAGCTCTAGGAGCATGTGfor 1 h and the reaction was stopped by cold 20 mM EDTA/PBS.
We detected the deposition of C3b by rat monoclonal antibody
against mouse C3 (Abcam, UK).2.3. Collagen-induced arthritis (CIA)
We immunized female mice with 100 ll of 2 mg/ml type II col-
lagen (IIC) (Sigma, USA) emulsiﬁed with complete Freund’s adju-
vant (CFA). CFA consisted of incomplete Freund’s adjuvant
(Thermo Scientiﬁc, USA) and 1.65 mg/ml heat-killed Mycobacte-
rium tuberculosis (H37Ra; Difco, USA), and was injected intrader-
mally at three sites near the base of the tail on day 0. On day 21,
mice were given booster injections near the former injection sites
with same amount of IIC/CFA intradermally. We judged the devel-
opment of arthritis by macroscopic evaluation. Arthritis develop-
ment in each paw was graded as follows: 0 = no change; 1 = mild
swelling; 2 = obvious joint swelling; 3 = severe joint swelling and
ankylotic changes [16].2.4. Histopathology
Mice were sacriﬁced under ether anesthesia and ankle joints of
hind limbs were removed, ﬁxed, decalciﬁed and parafﬁn embedded
for histopathology. Serial sections were stained with H&E. The le-
sions, including the calcaneus bone and anterior and posterior
synovial tissues of the ankle joints, were evaluated histopatholog-
ically. Each joint was graded on a scale of 0–3, where 0 = normal,
1 = thickening and proliferation of the synovial lining, with slight
inﬂammatory cell inﬁltration, 2 = grade 1 changes plus granulom-
atous lesions in the synovial sublining tissue, and 3 = grade 2
changes plus pannus formation and bone destruction. Arthritis in-
dex of the ankle joint was estimated from the average grade of ta-
lus and around bones including tibia and calcaneum of each mouse
[16].2.5. C3a and C5a titration
C3a and C5a levels in plasma were measured by ELISA with the
capture antibody–coated plates and detection antibodies against
C3a or C5a (BD Pharmingen, USA), using 10 mM EDTA-chelated
sera from female mice (8–10 weeks of age).2.6. Synoviocyte culture
The primary synoviocytes were harvested from synovium of
knee and ankle and were cultured in DMEM medium (Gibco) con-
taining 10% FBS and 1% penicillin-streptomycin. Cells were stimu-
lated with IL-1a (0, 1, 5 and 10 pg/ml) for 24 h in the absence or
presence of 1 ng/ml human recombinant CTRP3 (Adipobioscience,
USA). IL-6 levels in the culture supernatants after 24 h were mea-
sured with Mouse IL-6 ELISA MAX™ Standard (BioLegend, USA).2.7. Flow cytometric analysis
For ﬂow cytometry, cells were stained with Paciﬁc-Blue-, FITC-,
and APC-conjugated monoclonal antibodies (mAbs), as previously
described [17]. We purchased rat or hamster mAbs to mouse
CD3 (145-2C11) and B220 (RA3-6B2) from Biolegend (USA) and
CD11c (HL3) from BD Pharmingen (USA). Cells were stained
according to standard techniques, and analyzed by a FACS Canto
II cytometer and either CellQuest (BectonDickinson, USA) or FlowJo
software (Tree Star, USA).
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Fig. 1. Generation of C1qtnf3/ mice. (A) The expression of C1qtnf3mRNA in the joints of WT mice (WT), HTLV-I Tg mice (Tg), and IL-1 Ra KO mice (KO) were determined by
quantitative RT-PCR. (WT: n = 6, Tg: n = 6, and KO: n = 7). Average and SEM are shown. ⁄P < 0.01, ⁄⁄P < 0.001. (B) The expression of C1qtnf3 mRNA in immune cells was
determined by RT-PCR. The data were reproduced in another independent experiment with similar results. (C) ClustalW alignment of the C1q domain of human and mouse
CTRP3 amino acid sequences. The Gene ID of human and mouse C1qnf3 are 114899 and 81799, respectively. Identical amino acids are shown as white text on black
background. The amino acid identity of signal sequence, N-terminal variable region, collagen domain and C1q domain between human and mouse is 72% (16/22), 95% (21/22),
99% (68/69) and 99% (127/128), respectively. (D) Structure of mouse C1qtnf3 locus (WT allele), the C1qtnf3 targeting construct (Targeting vector), and the predicted mutated
C1qtnf3 gene (MT allele). Exons are represented by black boxes. For negative selection, a DT gene was attached to the 50 end of the genomic fragment. SacII (S) in the targeting
vector was used for linearization. (E) The homologous recombination of the C1qtnf3 locus of ES cells was examined in the EcoRI (E)- or HindIII (H)-digested genome by
Southern blotting using the 50 probe (upper) or 30 probe (lower), respectively. The clone 1 was used for the generation of the C1qtnf3/ mice. (F) The lack of C1qtnf3
transcripts from kidney was conﬁrmed by RT-PCR, using the primers in the ﬁgure (-> <-).
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LN cells were harvested from mice at day 7 after IIC-immuniza-
tion. LN cells were cultured in the absence or presence of 100 or200 lg/ml denatured IIC for 72 h, followed by incorporation of
[3H] thymidine (0.25 lCi/ml) (Amersham, UK) for 6 h. Then cells
were harvested with Micro 96 cell harvester (Skatron, Norway)
and radioactivity was measured with Micro Beta (Pharmacia
M.A. Murayama et al. / Biochemical and Biophysical Research Communications 443 (2014) 42–48 45Biotech, USA). IFN-c levels in the culture supernatants from the
proliferation assay after 72 h were measured with Mouse IFN-gam-
ma DuoSet (R&D Systems, USA).2.9. IIC-speciﬁc antibody titration
IIC-speciﬁc IgG levels were measured in sera from mice on day
42 after IIC/CFA-immunization by ELISA using 20 lg/ml IIC-coated
plates and alkaline phosphatase-conjugated polyclonal rabbit anti-
bodies to mouse IgG (Zymed, USA).2.10. In vitro B cell proliferation assay
Splenic B cells were puriﬁed by anti-mouse B220 microbeads,
according to manufacture’s instructions (Miltenyi Biotec,
Germany). B220+ cells were cultured with anti-mouse IgM F(ab)’2
fragment (0, 1, 5 and 10 lg/ml) (Jackson ImmunoResearch, USA)
for 72 h, followed by incorporation of [3H] thymidine (0.25 lCi/ml)
(Amersham, UK) for 6 h. Then, the radioactivity in harvested cells
was measured.2.11. In vitro neutrophil activation
Neutrophils were puriﬁed from bone marrow by anti-mouse
Ly-6G microbeads (Miltenyi Biotec, Germany). Neutrophils were
cultured with C5a (0, 0, 1 and 1 lg/ml) (R&D Systems, USA) for
1 h. Then, IL-1b levels in the supernatants were measured by
Mouse IL-1b ELISA MAX™ Standard (Biolegend, USA).0
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Fig. 2. CIA is exacerbated in C1qtnf3/ mice. (A, B) Incidence (A) and severity score (B) of
C1qtnf3/ n = 17). (C, D) Histopathology (C) and histological score (D) of the joints at da
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Incidence of CIA was evaluated by the v2 test, and the severity
score by the Mann–Whitney U-test. Two-sided Student’s t-test was
used for all other statistical evaluations.
3. Results
3.1. Generation of C1qtnf3/ mice
We previously identiﬁed C1qtnf3 as a candidate for autoim-
mune related gene based on the comprehensive gene expression
analysis using DNA microarrays of two RA models; HTLV-I Tg mice
and IL-1Ra KOmice [6]. We conﬁrmed the augmentation of C1qtnf3
expression in the joints of RA models using qPCR techniques. We
also found that the C1qtnf3 mRNA was expressed in neutrophils
and dendritic cells (DCs) (Fig. 1A and B).
Then, to elucidate the pathogenic roles of CTRP3 in the develop-
ment of autoimmune arthritis, we have generated C1qtnf3/ mice.
C1q domain is highly conserved between humans and mice
(Fig. 1C), Thus, we generated C1qtnf3/mice by deletion the C1q do-
main-encoding exon 4 (Fig. 1D). We conﬁrmed correct targeting of
the C1qtnf3 locus and the lack of C1qtnf3 transcript (Fig. 1E and F).
C1qtnf3/ mice were fertile, and were born in the expected Mende-
lian ratios, and showednoobviousabnormalities before1 yearof age.
3.2. C1qtnf3/ mice are susceptible to CIA
To assess the role of CTRP3 in the development of autoimmune
arthritis, we next examined the development of CIA in C1qtnf3/0
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mice was markedly increased compared to WT mice (Fig. 2A and
B). Also, histological examination of the ankle joints of WT mice
at day 42 after ﬁrst IIC/CFA-immunization under this regimen
showed mild pathological changes. In contrast, that of C1qtnf3/
mice showed much severe changes, including proliferation of
synovial lining cells, inﬁltration of inﬂammatory cells, and bone
destruction associated with pannus formation (Fig. 2C and D).
These results suggested that CTRP3 suppresses the development
of CIA.
3.3. Inﬂammation is enhanced in the joints of C1qtnf3/ mice
Because CTRP3 has C1q domain, we examined the possibility
that CTRP3 is involved in the complement system. We measured
the levels of complement active product C3a and C5a in plasma
at day 7 after IIC/CFA-immunization. The result showed C3a and
C5a levels in C1qtnf3/ mice were similar to that in C1qtnf3+/+
mice (Fig. 3A and B). Furthermore, we found that CTRP3 deﬁciency
did not inﬂuence complement activation in vitro (Fig. 3C). These
observations indicate that CTRP3 is not complement regulator.
Next, we examined the expression of inﬂammatory cytokines in
the joints at day 42 after IIC/CFA-immunization. The result showed
that cytokine production was enhanced in C1qtnf3/ mice than
WT mice (Fig. 3D). Because these cytokines are supported to be re-
leased from synoviocytes, we examined whether CTRP3 deﬁciency
directly affected inﬂammatory cytokine production from these
cells. We cultured synoviocytes from joints, and after stimulation
with IL-1a, IL-6 levels in the supernatants of the culture were mea-
sured by ELISA. The result showed that IL-6 from synoviocyte of
C1qtnf3/ mice was similar to that of WT mice, and exogenous
CTRP3 did not suppress IL-6 release from synoviocytes (Fig. 3D).IL
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3.4. IIC-speciﬁc B cell response is enhanced in C1qtnf3/ mice
Inﬁltration of T cells and B cells into synovial lining and periar-
ticular space is commonly observed in RA patients as well as RA
models. We found that T cell and B cell was increased in LNs of
C1qtnf3/ mice than that of WT mice at day 42 after the IIC/
CFA-immunization, but the cell population was unchanged
(Fig. 4A and B). Then, LN cells were harvested from mice at day 7
after IIC/CFA-immunization and the proliferative response against
IIC was examined. We found that recall T cell proliferation re-
sponse was comparable between C1qtnf3/ mice and WT mice
(Fig. 4C). IFN-c production after IIC re-stimulation was also compa-
rable between C1qtnf3/ and WT LN cell cultures (Fig. 4D). These
results suggest that T cell priming in C1qtnf3/ mice is normal.
Next, we examined production of IIC-speciﬁc IgG in C1qtnf3/
mice at day 42 after IIC/CFA-immunization. The results showed
that IIC-speciﬁc IgG levels in sera from C1qtnf3/ mice were sig-
niﬁcantly higher than that of WTmice (Fig. 4E). Then, we examined
the effect of CTRP3 on B cell proliferation in vitro. However, the B
cell proliferation induced by anti-IgM was comparable between
C1qtnf3/ B cells and WT B cells, and exogenous CTRP3 did not
suppress B cell proliferation (Fig. 4F).
Furthermore, we examined the effect of CTRP3 on neutrophil
activation because C1qtnf3 was expressed in neutrophils (Fig. 1B).
Neutrophils from bone marrows were stimulated with C5a, and
IL-1b levels in the culture supernatants were measured by ELISA.
The results showed that IL-1b production from C1qtnf3/ neutro-
phils was similar to that of WT mice, and exogenous CTRP3 did notWT C1qtnf3-/-
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Fig. 4. IIC-speciﬁc antibody production was enhanced in C1qtnf3/mice. (A, B) At day 42 after IIC/CFA immunization, the number of total cells, T cells, B cells and DCs (A) and
their relative contents (B) in inguinal LNs were analyzed using CD4-, B220- and CD11c-speciﬁc antibodies by ﬂow cytometry (WT: n = 9, C1qtnf3/: n = 11). Similar results
were obtained in another independent experiment. (C, D) Seven days after IIC/CFA immunization, inguinal LN cells were removed and cultures with IIC (0, 100, 200 mg/ml).
Then, IIC-speciﬁc proliferative response was measured by [3H] TdR incorporation (C). IFN-c concentration in the culture supernatant was determined (WT, C1qtnf3/: n = 4
each) (D). Similar results were obtained in another independent experiment. (E) At day 42 after IIC/CFA immunization, the sera were collected and IIC-speciﬁc IgG levels were
determined by ELISA. The data from two independent experiments are combined and shown (WT: n = 16 and C1qtnf3/: n = 17). (F) B cells were incubated with anti-IgM Ab
(0–10 mg/ml) and CTRP3 (0, 10, 100 ng/ml). Then, the proliferative response was measured by [3H] TdR incorporation (WT, C1qtnf3/: n = 3 each). (G) IL-1b production from
neutrophils after C5a stimulation (0–1 ng/ml) in the presence of CTRP3 (0–500 ng/ml) was measured by ELISA (WT, C1qtnf3/: n = 3 each). All data were reproducible in
another independent experiment. ⁄P < 0.05, ⁄⁄P < 0.01. Average and SEM are shown.
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tions suggest that CTRP3 plays an important role in the develop-
ment of autoimmune arthritis by regulating antibody production.
4. Discussion
In this report, we have generated C1qtnf3/ mice and examined
the development of CIA in these mice, because C1qtnf3 expression
is highly enhanced in the joints of three RA models; HTLV-I Tg
mice, Il1rn/ mice and K/BxN mice [18]. We showed that the
development of CIA was greatly exacerbated in C1qtnf3/ mice,
suggesting a regulatory role for CTRP3 in the development of auto-
immune arthritis. We found that antibody production against IIC
was signiﬁcantly increased in C1qtnf3/ mice after induction of
CIA. Because antibody production against IIC is crucial for the
development of arthritis, this deﬁciency is suggested to be respon-
sible for the suppression of CIA in these mutant mice.
However, we detected no abnormality in recall proliferative re-
sponse against IIC in T cells frommutant mice. B cell intrinsic func-
tion was also normal, because B cell proliferative response was
normal after stimulation with anti-IgM. Furthermore, cytokine
production after neutrophil activation with complement compo-
nent C5a was normal, suggesting that neutrophils, one of high
CTRP3 producers, are not responsible for the elevated inﬂamma-
tion in joints. Although CTRP3 is reported to suppress inﬂamma-
tory cytokine release in human monocytes [10], CTRP3 did not
suppress the cytokine production in synovial resident/inﬁltrated
cells from arthritic joints.
CTRP3 is also implicated in chondrogenesis, because the prolif-
eration of chondrogenic precursor cells and chondrocytes was en-
hanced by this protein in vitro [8]. The involvement in thedevelopment of mandibular condylar cartilage is also suggested
[19]. However, we detected no obvious skeletal abnormalities in
C1qtnf3/ mice; they were fertile and were born in the expected
Mendelian ratios without any obvious skeletal deformity. It is pos-
sible that the effects of CTRP3-deﬁciency are compensated by other
CTRP family members, because other CTRP family members, such
as adiponectin, are also involved in the regulation of chondrogen-
esis [20]. Involvement of CTRP family members in the regulation of
the complement system is also suggested, because adiponectin is
involved in the regulation of the complement CP by activating
C1q [21] and of the AP in collaboration with complement factor
H [22]. However, we detected no abnormalities of the complement
system in C1qtnf3/ mice, suggesting that CTRP3 is not involved in
the complement system.
Thus, probably excessive proliferation of T cells and B cells
found in C1qtnf3/ mice may be responsible for the increased
antibody production and exacerbation of arthritis in these mice.
However, it is difﬁcult to elucidate the exact roles of CTRP3 in anti-
body production, because the receptor for CTRP3 as well as the
receptor expressing cells has not been identiﬁed yet. Clearly, it re-
mains to be elucidated how CTRP3 regulates antibody production.
Nonetheless, our observations clearly demonstrate that CTRP3 can
alleviate the development of autoimmune arthritis, suggesting that
CTRP3 is a possible candidate of the medicine for the treatment of
RA and other autoimmune diseases.
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